NRX Pharmaceuticals
NRXP
19 hedge funds and large institutions have $41.4M invested in NRX Pharmaceuticals in 2018 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 6 increasing their positions, 2 reducing their positions, and 2 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 2
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
6% more capital invested
Capital invested by funds: $39.2M → $41.4M (+$2.19M)
6% more funds holding
Funds holding: 18 → 19 (+1)
0.2% more ownership
Funds ownership: 4.53% → 4.73% (+0.2%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$3.48M |
| 2 |
RCM
Rivernorth Capital Management
West Palm Beach,
Florida
|
+$1.78M |
| 3 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$1.26M |
| 4 |
PC
Periscope Capital
Toronto,
Ontario, Canada
|
+$995K |
| 5 |
HIM
HGC Investment Management
Toronto,
Ontario, Canada
|
+$503K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WAM
Weiss Asset Management
Boston,
Massachusetts
|
-$3.75M |
| 2 |
BFM
Boothbay Fund Management
New York
|
-$2.36M |
| 3 |
DAM
Deltec Asset Management
New York
|
-$732K |
| 4 |
BI
Bulldog Investors
Saddle Brook,
New Jersey
|
-$57.6K |
NRXP Hedge Fund Activity: Q2 2018 in Review
19 of the 4,385 institutional investors tracked by Wall St. Rank reported a position in NRX Pharmaceuticals (NRXP) for Q2 2018, worth a combined $41.4M — up 5.6% from $39.2M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new NRXP positions and 2 closed out — a net gain of 1 holder — while 6 added to existing stakes and 2 trimmed.
The largest buyer was Bank of Montreal, opening a new position worth an estimated $3.48M. The largest seller was Weiss Asset Management, exiting entirely with an estimated $3.75M sold.
- 19 institutional investors held NRX Pharmaceuticals (NRXP) as of Q2 2018, up from 18 in Q1 2018.
- Funds reported $41.4M of NRX Pharmaceuticals stock for Q2 2018, up 5.6% quarter-over-quarter.
- 3 funds opened new NRX Pharmaceuticals positions in Q2 2018 and 2 closed out, a net change of +1 holder.
- The largest NRX Pharmaceuticals buyer in Q2 2018 was Bank of Montreal, an estimated $3.48M added.
- The largest NRX Pharmaceuticals seller in Q2 2018 was Weiss Asset Management, an estimated $3.75M sold.
Based on aggregated 13F filings for Q2 2018.